G-CSF
Caitlin Soto, PharmD, BCIDP, Kathryn Dzintars, Pharm.D., BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Below are primarily filgrastim indications:
- Prevention of chemotherapy-associated febrile neutropenia in nonmyeloid malignancies
- Shortens neutrophil recovery time and fever after AML induction/consolidation.
- Neutropenia following bone marrow transplantation
- Autologous mobilization of hematopoietic progenitor cells for collection by leukapheresis
- Symptomatic severe chronic congenital, cyclic, or idiopathic neutropenia
- Increased survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
- Pegfilgrastim and tbo-filgrastim do not automatically share every indication.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Severe neutropenia associated with HIV and/or opportunistic infections
- Selected severe drug-induced neutropenia/agranulocytosis, particularly with infection or anticipated prolonged neutropenia.
- Prolonged β-lactam and vancomycin exposure are potential examples.
- Prolonged neutropenia/immune effector cell-associated hematologic toxicity (ICAHT) after CAR T-cell therapy.
- EHA/EBMT permits consideration of G-CSF from day +2 in selected patients at high risk for hematotoxicity. Timing should follow the cellular-therapy team’s protocol, product guidance, and concurrent CRS/ICANS.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.